High quality standards are essential for robust and reliable Biomarker Discovery and Verification as well as for the discovery of new Drug Targets. During the last 10 years a stringent quality assurance workflow has been established for our Antibody Array Platform in order to conduct immuno-based biomedical discovery studies with excellent standards in terms of reproducibility and platform stability. The automated assay workflow further improves the performance of our service.
Biomarker Discovery Phase - scioDiscover Platform
Stringent antigen design for maximised specificity of the resulting antibodies
Antibodies are antigen affinity-purified
Targets identified through transcriptional studies and expert input
Stringent QC management
Features:
cross-species activity (human and mouse for high versatility)
detection of several protein isoforms
cost-efficiency through high content
Verification Phase - Custom Array Platform
Stringent antigen design for maximised specificity of the resulting antibodies
Antibodies are antigen affinity-purified
In-house QC on Western Blot (different cell lines or tissues) and optional ELISA-based tests
In-house QC on large-scale protein arrays (> 9.000 human proteins)
In-depth validation of array performance
Definition of biomarker signature with highest accuracy
Selection of appropriate binders / sandwich pairs
Features:
specifically designed antibodies for further use in diagnostic assays
fully renewable antibody formats
in-depth quality controlled (WB, ELISA)
comprehensive cross-reactivity profile (large-scale protein arrays)
Orthogonal Biomarker Validation
Verified Candidates can be further validated by orthogonal methods according to customer’s requirements
High quality standards are essential for robust and reliable Biomarker Discovery and Verification as well as for the discovery of new Drug Targets. During the last 10 years a stringent quality assurance workflow has been established for our Antibody Array Platform in order to conduct immuno-based biomedical discovery studies with excellent standards in terms of reproducibility and platform stability. The automated assay workflow further improves the performance of our service.
Biomarker Discovery Phase - scioDiscover Platform
Stringent antigen design for maximised specificity of the resulting antibodies
Antibodies are antigen affinity-purified
Targets identified through transcriptional studies and expert input
Stringent QC management
Features:
cross-species activity (human and mouse for high versatility)
detection of several protein isoforms
cost-efficiency through high content
Verification Phase - Custom Array Platform
Stringent antigen design for maximised specificity of the resulting antibodies
Antibodies are antigen affinity-purified
In-house QC on Western Blot (different cell lines or tissues) and optional ELISA-based tests
In-house QC on large-scale protein arrays (> 9.000 human proteins)
In-depth validation of array performance
Definition of biomarker signature with highest accuracy
Selection of appropriate binders / sandwich pairs
Features:
specifically designed antibodies for further use in diagnostic assays
fully renewable antibody formats
in-depth quality controlled (WB, ELISA)
comprehensive cross-reactivity profile (large-scale protein arrays)
Orthogonal Biomarker Validation
Verified Candidates can be further validated by orthogonal methods according to customer’s requirements